Saniona a clinical stage biopharmaceutical company focused on rare diseases, today announced that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the next stage.
“After successful completion of target validation, library screening and generation of selective hits, Saniona and Boehringer Ingelheim have agreed to progress our ongoing ion channel research collaboration into the ‘hit-to-lead’ stage,” said Jørgen Drejer, Founder and Chief Scientific Officer of Saniona. “We look forward to continuing our partnership with Boehringer Ingelheim scientists as we work together to identify novel ion channel modulators to treat cognitive deficits in schizophrenia.”
Saniona and Boehringer Ingelheim entered into the ongoing research collaboration in 2020. The collaboration is focused on a novel, undisclosed CNS ion channel target for schizophrenia. Saniona receives ongoing research funding and may receive up to €76.5 million in milestone payments as well as royalties on worldwide net sales.